These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 34690930)

  • 21. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network.
    Gao Q; Zhang W; Li T; Yang G; Zhu W; Chen N; Jin H
    Sci Rep; 2022 Jan; 12(1):188. PubMed ID: 34996987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ACE2 as a Potential Target for Management of Novel Coronavirus (nCoV- 2019).
    Foroozanfar E; Forouzanfar M; Farkhondeh T; Samarghandian S; Forouzanfar F
    Curr Drug Discov Technol; 2021; 18(6):e130921189567. PubMed ID: 33371835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.
    Stoian AP; Papanas N; Prazny M; Rizvi AA; Rizzo M
    J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):494-496. PubMed ID: 32618198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane?
    Jagat J M; Kalyan K G; Subir R
    Diabetes Metab Syndr; 2020; 14(5):829-831. PubMed ID: 32540737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissecting the interaction between COVID-19 and diabetes mellitus.
    Chee YJ; Tan SK; Yeoh E
    J Diabetes Investig; 2020 Sep; 11(5):1104-1114. PubMed ID: 32558211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study.
    Parit R; Jayavel S
    Eur J Pharmacol; 2021 Apr; 896():173899. PubMed ID: 33508281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type-2 diabetes, a co-morbidity in Covid-19: does insulin signaling matter?
    Mishra D; Dey CS
    Biochem Soc Trans; 2021 Apr; 49(2):987-995. PubMed ID: 33666220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2.
    Israelsen SB; Pottegård A; Sandholdt H; Madsbad S; Thomsen RW; Benfield T
    Diabetes Obes Metab; 2021 Jun; 23(6):1397-1401. PubMed ID: 33502076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential.
    Kamyshnyi O; Matskevych V; Lenchuk T; Strilbytska O; Storey K; Lushchak O
    Biomed Pharmacother; 2021 Dec; 144():112230. PubMed ID: 34628168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.
    Bielka W; Przezak A; Pawlik A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 and diabetes; Possible role of polymorphism and rise of telemedicine.
    Sayed S
    Prim Care Diabetes; 2021 Feb; 15(1):4-9. PubMed ID: 32912711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation.
    Aboudounya MM; Heads RJ
    Mediators Inflamm; 2021; 2021():8874339. PubMed ID: 33505220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.
    Wang Y; Takeshita H; Yamamoto K; Huang Y; Wang C; Nakajima T; Nozato Y; Fujimoto T; Yokoyama S; Hongyo K; Nakagami F; Akasaka H; Takami Y; Takeya Y; Sugimoto K; Rakugi H
    FASEB J; 2021 Mar; 35(3):e21419. PubMed ID: 33566370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
    Sallenave JM; Guillot L
    Front Immunol; 2020; 11():1229. PubMed ID: 32574272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL
    Mouffouk C; Mouffouk S; Mouffouk S; Hambaba L; Haba H
    Eur J Pharmacol; 2021 Jan; 891():173759. PubMed ID: 33249077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.